Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Jiang A"'
Autor:
Marek Trněný, Kathryn Humphrey, Nathalie A. Johnson, Sven de Vos, Gilles Salles, Farheen Mir, Richard Greil, Yanwen Jiang, Elizabeth Punnoose, Robin Gasiorowski, Arijit Sinha, Su Y. Kim, Caterina Patti, Emma Clark, Andrew D. Zelenetz, Jean-François Larouche, Nathalie Spielewoy, Divya Samineni, Alexandra Bazeos, Franck Morschhauser, Pierre Feugier, Pieternella J. Lugtenburg, Árpád Illés, Ian W. Flinn
Publikováno v:
Blood, 137(5), 600-609. American Society of Hematology
Blood
Blood
The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse la
Autor:
Steven J. Schrodi, Peng An, Minghua Wang, Robert Strenn, Narendranath Epperla, Wenyu Wu, Terrie Kitchner, Fudi Wang, Jiucun Wang, Jennifer K. Meece, Joseph J. Mazza, Zhan Ye, Mehdi Maadooliat, Shuai Jiang, Jeffrey Joyce, Yanyun Ma, Brent F. Olson, Shicheng Guo, Judith A. Smith, Li Jin
Publikováno v:
Blood. 133:1888-1898
Standard analyses applied to genome-wide association data are well designed to detect additive effects of moderate strength. However, the power for standard genome-wide association study (GWAS) analyses to identify effects from recessive diplotypes i
Autor:
Andrew J. Mungall, Waleed Alduaij, Merrill Boyle, Kerry J. Savage, Tomoko Miyata-Takata, Christian Steidl, David W. Scott, Randy D. Gascoyne, Susana Ben-Neriah, Jeffrey W. Craig, Pedro Farinha, Aixiang Jiang, Diego Villa, Alina S. Gerrie, Graham W. Slack, Brett Collinge, Barbara Meissner, Laurie H. Sehn, Laura K. Hilton, Ciara L. Freeman, Joseph M. Connors
Publikováno v:
Blood. 138:1458-1458
Introduction: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH), colloquially referred to as double- or triple-hit lymphoma, is associated with poor outcomes prompting many centers to use dose-intensive immunochemot
Autor:
Hao Chen, Changqing Zhen, Huiting Qu, Ying Li, Xiaosheng Fang, Chao Xue, Xin Wang, Yujie Jiang, Hongzhi Xu, Lingyan Zhang, Mei Ding, Qian Zhang, Xiaohui Sui
Publikováno v:
Blood. 136:27-28
Background: Late-onset hemorrhagic cystitis (LO-HC) is one of the common complications and major causes of morbidity in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The classic treatment for HC includes hydratio
Autor:
Fuhong He, Zhang Lin, Yanxun Su, Yongping Zhang, Haiyang Hu, Aili Chen, Shuting Jiang, Jun Lu, Peifang Xiao, Li Gao, Qianfei Wang, Zihan Zhou, Yixin Hu, Dan Liu, Raul C. Ribeiro, Lei Qin, Shaoyan Hu, Liyan Fan
Publikováno v:
Blood. 136:25-26
Although majority of pediatric acute myeloid leukemia (pAML) undergo complete remission (CR) after chemotherapy, more than 30% of which eventually relapse, leading to a dismal outcome. Chemo-resistant cells at CR, measured as minimal residual disease
Autor:
Zaid Abdel Rahman, Michael G. Heckman, James M. Foran, Yesesri Cherukuri, Liuyan Jiang, Yan W. Asmann, Laura Finn, James R. Cerhan, Lisa Z. Sproat
Publikováno v:
Blood. 136:35-36
Introduction: Population studies have identified genes with germline polymorphisms associated with acute myeloid leukemia (AML) risk and outcome. However, somatic mutations in these genes have not been reported in an AML clinical population and wheth
Autor:
Zi Chen, Hengbang Wang, Qian Jiang, Ping Liu, Qian Niu, Tanhong Xie, Chenhui Deng, Dajun Yang, Yifan Zhai, Ping Xu, Ming Lu, Lichuang Men, Yifeng Xiong
Publikováno v:
Blood. 136:5-6
Introduction Olverembatinib (HQP1351), a third-generation BCR-ABL1 inhibitor, has been rationally developed to treat patients with CML that is refractory to or intolerant of tyrosine kinase inhibitors (TKIs), including acquired drug-resistant mutatio
Autor:
Delphine Rea, Michael J. Mauro, Jorge E. Cortes, Qian Jiang, Katia B Pagnano, Matilda Ongondi, Chung Hoow Kok, Nicola Evans, Timothy P. Hughes, International CML Foundation
Publikováno v:
Blood
Background Comorbid conditions, including solid and hematologic malignancies, may impact risk of contracting SARS CoV-2 or having severe COVID-19. Data specific to individual cancer types is essential to differentiate impact of patient, disease, and
Autor:
Yvonne A. Efebera, Sam Penza, Jonathan E. Brammer, Sarah A Wall, Nicole Grieselhuber, Alice S. Mims, Basem M. William, Maria Chaudhry, Patrick Elder, Karilyn Larkin, Don M. Benson, Sumithira Vasu, Ayman Saad, Samantha Jaglowski, Srinivas Devarakonda, Audrey M. Sigmund, Qiuhong Zhao, Hannah Choe, Ashley E. Rosko, Naresh Bumma, Abdullah Khan, Nidhi Sharma, Justin Jiang
Publikováno v:
Blood. 136:42-42
Introduction-Chronic graft-versus-host disease (cGVHD) poses as a major late complication of hematopoietic stem cell transplantation. The role of cGVHD as a determinant in transplant-related morbidity and mortality, infectious complications, prolonge
Autor:
Yongping Song, Pei Hu, Katherine Chai, Xiaonan Hong, Dong Wang, Xiaohong Han, Xiaofeng Zeng, Kevin Li, Weidong Jiang, Kaka Y. Hong, Yan Qin, Shuiyu Zhao, Alvin Luk, Xin Zhang, Chaoming Ma, Qingyuan Zhang, Scott Liu, Peng Ting, Dan Yao, Yuankai Shi, Eugene Liu, Jiancheng Cheng
Publikováno v:
Blood. 134:2878-2878
Background In February 2019, the National Medicinal Products Administration (NMPA) approved the first China-manufactured rituximab (RTX) biosimilar, HLX01, for the treatment of non-Hodgkin's lymphoma in accordance to the development of biosimilar gui